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Abstract Preclinical studies suggest that stem cell therapy
(SCT) may improve sensorimotor recovery after stroke.
Upper extremity motor impairment (UEMI) is common after
stroke, often entailing substantial disability. To evaluate the
feasibility of post-stroke UEMI as a target for SCT, we exam-
ined a selected sample of stroke patients potentially suitable
for SCT, aiming to assess the frequency and recovery of
UEMI, as well as its relation to activity limitations and partic-
ipation restrictions. Patients aged 20–75 years with first-ever
ischemic stroke, and National Institutes of Health Stroke Scale
(NIHSS) scores 1–18, underwent brain diffusion-weighted
MRI within 4 days of stroke onset (n = 108). Survivors were
followed up after 3–5 years, including assessment with
NIHSS, Fugl-Meyer assessment of upper extremity (FMA-
UE), modified Rankin Scale (mRS), and Stroke Impact
Scale (SIS). UEMI was defined as NIHSS arm/hand score
≥1. UEMI recovery was evaluated with change in NIHSS
arm/hand scores between baseline and follow-up. Of 97 sur-
vivors, 84 were available to follow-up. Among 76 subjects (of
84) without recurrent stroke, 41 had UEMI at baseline of
which 10 had residual UEMI at follow-up. The FMA-UE
showed moderate-severe impairment in seven of 10 survivors
with residual UEMI. UEMI was correlated to mRS (rs = 0.49,
p < 0.001) and the SIS social participation domain (rs = −0.38,
p = 0.001). Nearly 25% of the subjects with UEMI at baseline
had residual impairment after 3–5 years, whereas about 75%
showed complete recovery. Most of the subjects with residual
UEMI had moderate-severe impairment, which correlated
strongly to dependency in daily activities and social participa-
tion restrictions. Our findings suggest that SCT targeting post-
stroke UEMI may be clinically valuable with significant
meaningful benefits for patients but also emphasize the need
of early prognostication to detect patients that will have resid-
ual impairment in order to optimize patient selection for SCT.
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Introduction
Stem cell therapy (SCT) has emerged as a potential thera-
peutic option for functional restoration after the acute
phase of stroke [1]. Effects of tissue-specific neural stem
cells and non-tissue-specific mesenchymal stem cells have
been associated with improved functional recovery in ani-
mal models of stroke, mediated through mechanisms such
as trophic effects, modulation of inflammation, neuropro-
tection, stimulation of angiogenesis, and possibly by neu-
ronal replacement [2, 3]. Clinical stroke trials with SCT are
ongoing, mostly investigating safety in limited numbers of
selected patients [3–6]. However, the efficacy of SCT for
stroke patients remains to be demonstrated, and the choice
of which outcome variables to study is a crucial issue for
the optimal design of later-phase pivotal trials.
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Stroke lesion sizes and locations are highly heterogeneous,
and the clinical manifestations of stroke are also diverse
encompassing a broad variety of neurological impairments
and varying degrees of severity. Correspondingly, there is
much inter-individual variation in functional recovery after
stroke [7]. Furthermore, the rates and extent of recovery also
differ depending on the type of neurological impairment [8].
Consequently, SCT may have varying effects on different as-
pects of functional recovery after stroke. To demonstrate the
maximum potential treatment effect, it has therefore been sug-
gested that domain-specific outcomes may be best suited as
end-points in stroke trials aiming to study the efficacy of
SCT [8].
Recovery of impaired motor functions after stroke, such as
recovery of upper extremity motor impairment (UEMI), may
be one such well-defined domain-specific outcome. UEMI is
especially interesting in this regard as preclinical SCT studies
have mainly focused on recovery of sensorimotor functions
after stroke [3, 8], and behavioral assessments in rodent stroke
models have demonstrated that SCTcan significantly improve
forelimb motor function [9–12]. In humans, UEMI can be a
major consequence following stroke and may entail substan-
tial disability causing dependency in activities of daily living
(ADLs) and reduced health-related quality of life (HRQoL)
[13–15]. In addition, UEMI can readily be evaluated objec-
tively with commonly used clinical assessment measures [16].
However, the feasibility of UEMI as a target for SCT in stroke
patients is unclear.
We therefore examined a selected group of ischemic stroke
patients, potentially suitable for SCT, assessing (i) the propor-
tion and characteristics of subjects with UEMI, (ii) the degree
of spontaneous recovery of UEMI during a 3–5-year period
after stroke, and (iii) the relation of UEMI to activity limita-
tions and participation restrictions after stroke.
Methods
Sample
The study sample (n = 108) was recruited from a consecutive
series of first-ever ischemic stroke patients admitted to Skåne
University Hospital in Lund, Sweden, in 2009–2011. Stroke
was defined by theWorld Health Organization (WHO) criteria
[17]. CT of the head was performed on all patients to exclude
intracranial hemorrhage.
To select stroke patients potentially suitable for SCT, pa-
tients were prospectively included at baseline if they were
aged 20–75 years, had a National Institutes of Health Stroke
Scale (NIHSS) score of 1–18 on days 2–4 after stroke onset
[18], could perform diffusion-weightedMRI (DW-MRI) with-
in 4 days of stroke onset, and gave written informed consent to
participate. Exclusion criteria were symptoms or CT findings
strongly suggestive of brainstem or cerebellar infarction, se-
vere concomitant disease, or contraindications toMRI. Details
on case ascertainment at baseline, as well as baseline assess-
ments and variables, have been previously described [19].
Follow-up Procedure
Clinical follow-up examination was performed by a physi-
cian (blinded to the baseline data) for each participating
stroke survivor 3–5 years after stroke onset at the outpatient
clinic of the Department of Neurology and Rehabilitation
Medicine at Skåne University Hospital. Stroke survivors
unable to come to the outpatient clinic were offered
follow-up through home visit.
Clinical Assessments
The clinical assessment protocol at follow-up conformed to
the WHO International Classification of Functioning,
Disability and Health [20], including evaluations at the levels
of body functions and structures, activity, and participation,
as follows:
1. Body functions and structures
The NIHSS was used to measure the severity of stroke
symptoms [18]. Similar to previous studies, we also included
the assessment of distal upper limb motor function by adding
the additional item for motor function in the hand (NIHSS
item 12; scores 0–2) to the official NIHSS (composite scores
0–46) [21]. Overall stroke severity was stratified according to
the NIHSS scores as follows: no symptoms = 0, mild = 1–4,
moderately severe = 5–14, and severe = ≥15 [22].
UEMI was defined as a score of ≥1 on the combined
NIHSS arm and hand items (composite scores 0–6). In case
of bilateral UEMI, the mostly impaired side was evaluated
throughout the study. The NIHSS was also used for the lon-
gitudinal assessment of the recovery of UEMI between base-
line and follow-up (ΔNIHSS arm/hand). The Fugl-Meyer
Assessment of Upper Extremity (FMA-UE, scores 0–66)
was used for more detailed evaluation of the stroke survivors
with UEMI [23]. FMA-UE consists of 33 items that are divid-
ed into the following subsections: shoulder-arm (scores 0–36),
wrist (scores 0–10), hand (scores 0–14), and upper limb coor-
dination (scores 0–6) [23]. The degree of UEMI was defined
on the basis of FMA-UE scores as follows: severe = 0–22,
moderate = 23–52, and mild = 53–66 [24, 25].
2. Activity
The modified Rankin Scale (mRS, scores 0–5) was used to
assess the degree of functional independence in ADL with
reference to pre-stroke activities [26]. In addition, the upper
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extremity functioning at the level of activities was evaluated
with the Action Research Arm Test (ARAT, scores 0–57) [27,
28]. The ARAT contains 19 items grouped into the following
subtests: grasp (scores 0–18), pinch (scores 0–12), grip (scores
0–18), and gross movement (scores 0–9) [27, 28]. The upper
extremity functional capacity was defined according to the
followingARATcut-points as follows: none=0–10, poor=11–
21, limited = 22–42, notable = 43–54, or full = 55–57 [24].
3. Participation
HRQoL was assessed using the Stroke Impact Scale (SIS),
version 2.0, which evaluates the patient-reported impact of
stroke on different domains of health and life including ADL
and social participation [29]. The first question of the Short-
Form 36 Health Survey (SF-36) was used to assess the
patient-reported overall health status (BIn general, would you
say your health is: excellent, very good, good, fairly good, or
poor?^) [30].
Imaging and Image Interpretation
The MR imaging procedure at baseline has been previously
described [19]. In summary, all patients were examined with
transversal DW-MRI as well as transversal FLAIR-, GRE-, and
sagittal T2-weighted sequences within 4 days of stroke onset. A
neuroradiologist blinded to the clinical information analyzed
the images. Extent of acute focal ischemic lesions was defined
as the area of restricted diffusion on diffusion-weighted se-
quences. For stroke patients with UEMI, we also assessed the
ischemic lesions’ possible involvement of the motor cortex in-
cluding the primary motor cortex, the premotor areas, and the
supplementary motor areas. Likewise, we assessed the possible
involvement of the corticospinal tract by estimating the location
of the corticospinal tract on MR imaging using previously
established neuroradiological methods [31].
To illustrate the ischemic lesions in stroke patients with
UEMI, a lesion overlap map was created. The identified
lesions on the DW-MRI sequences were manually drawn
on the closest corresponding slices of the ICBM 2009a
Nonlinear Symmetric 1 × 1 × 1 mm T1-weighted template
(supplied by McConnell Imaging Center, Montreal,
Canada), using MRIcron software [32, 33]. In order to sim-
plify the overlap map, the lesions were oriented such that
the clinically relevant stroke lesions were assumed to be in
the left hemisphere. The lesion overlap plot was then ob-
tained using the MRIcron software.
Statistical Analysis
The Mann-Whitney two-sample test and Fisher’s exact test
were used for comparisons with continuous and categorical
variables, respectively. Spearman’s rank-order correlation was
used to evaluate the relation of UEMI (defined as NIHSS arm/
hand score ≥1) to the degree of independence in ADL as
measured with mRS, HRQoL as assessed with the SIS do-
mains regarding ADL and social participation, as well as with
the first question of SF-36 regarding overall health status. p-
values <0.05 were considered significant. The statistical cal-
culations were performed using SPSS software (version 22,
released 2013; IBM SPSS Statistics for Windows, IBM Corp,
Armonk, NY).
Results
Of the 108 stroke patients included at baseline, 11 (10%) were
deceased at the time of follow-up. In total, 84 (87%) of the 97
stroke survivors performed the clinical follow-up examina-
tion. The dropout reasons and sample flow from baseline to
follow-up are illustrated in Fig. 1, and the details on demo-
graphic and baseline characteristics of the included stroke sur-
vivors versus the deceased stroke patients are presented in
Table 1.
Characteristics of Stroke Patients at Follow-up
The median age of the 84 included stroke survivors was
68 years (range 33–80), and 30 (36%) of these were female.
The median time from stroke onset to follow-up was 4.6 years
(range 3.5–5.7). In total, 41/84 stroke survivors had received
some form of rehabilitation therapy after the index stroke,
with a median time of rehabilitation of 5 weeks (range 1–
109). Recurrent strokes were reported for 8/84 stroke survi-
vors. Further details on follow-up characteristics of the includ-
ed stroke survivors are presented in Table 2.
Frequency and Characteristics of Stroke Patients
with UEMI
Among the 76 stroke survivors with no recurrent stroke, 41
had UEMI at baseline of whom 10 displayed residual UEMI
after 3–5 years. Analysis of the DW-MRIs showed
corticosubcortical infarcts in 14/41 stroke survivors with
UEMI at baseline, all involving the motor cortex and/or the
estimated course of the corticospinal tract. Sole cortical in-
farcts were observed in 3/41 stroke survivors, all with motor
cortex involvement. Moreover, only subcortical infarcts were
seen in 19/41 stroke survivors, and the estimated course of the
corticospinal tract was involved in 12 of these cases. In addi-
tion, 2/41 stroke survivors had brainstem infarcts (without
clear localizing symptoms from the brainstem), and 3/41 had
MRI negative strokes. The MRI overlap image showing the
brain infarcts of the stroke survivors with UEMI at baseline is
presented in Fig. 2.
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Table 1 Demographics and
baseline characteristics for
included ischemic stroke patients
Variable Survivors (n = 84) Deceased before
follow-upa (n = 11)
Sex, n (%)
Female 30 (36) 3 (27)
Age at stroke onset, median (range) 64 (28–75) 67 (60–71)
Acute recanalization treatmentb, n (%) 13 (15) 1 (9)
NIHSS on days 2–4 after stroke onset, median (range) 3 (1–18) 3 (1–7)
UEMI on days 2–4 after stroke onset, n (%) 44 (52) 5 (46)
NIHSS National Institutes of Health Stroke Scale, including hand item 12 (composite scores 0–46); UEMI upper
extremity motor impairment, defined as the NIHSS arm/hand score of ≥1
a The median time from index stroke to death was 31 months (range 0–57)
b Thrombolysis and/or endovascular treatment
Fig. 1 Patient flowchart. The age
indicated is age at stroke onset
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Spontaneous Recovery of UEMI in Stroke Patients
Among the stroke survivors with UEMI at baseline, 31/41
showed complete recovery at follow-up. Of the 10/41 stroke
survivors with residual UEMI at follow-up, 5/10 displayed
only partial recovery whereas the other 5/10 showed no recov-
ery at all. Of these 10 individuals with residual UEMI, 3 had a
mild degree of residual impairment (FMA-UE = 53–66), 4 had
Fig. 2 Lesion overlap image of
the stroke survivors with upper
extremity motor impairment at
baseline (n = 41 stroke survivors
without recurrent stroke). The
lesions were oriented such that the
clinically relevant stroke lesions
were assumed to be in the left
hemisphere. The color bar
indicates the number of
overlapping lesions, and the
enlarged picture shows the slice
with the maximum number of
overlapping lesions
Table 2 Follow-up
characteristics of the included
ischemic stroke survivors
Variable Survivors without recurrent
stroke (n = 76)
Survivors with recurrent
stroke (n = 8)
Sex, n (%)
Female 26 (34) 4 (50)
Age at follow-up, median (range) 68 (33–80) 72 (62–77)
Stroke severitya, n (%)
No symptoms 40 (53) 2 (25)
Mild 31 (41) 4 (50)
Moderately severe 5 (7) 2 (25)
Severe 0 0
Overall disabilityb, n (%)
No/slight 71 (93) 5 (63)
Moderate 4 (5) 1 (13)
Severe 1 (1) 2 (25)
a Overall stroke severity was classified according to the National Institutes of Health Stroke Scale including hand
item 12 (NIHSS, composite scores 0–46), as follows: no symptoms = 0, mild = 1–4, moderately severe = 5–14,
and severe = ≥15
bOverall disability was classified according to the modified Rankin Scale (mRS, scores 0–5), as follows: no/
slight = 0–2, moderate = 3, and severe = 4–5
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a moderate degree of residual impairment (FMA-UE = 23–52),
and 3 had severe residual impairment (FMA-UE = 0–22). The
spontaneous recovery of UEMI is illustrated in Fig. 3.
The stroke survivors with partial or no UEMI recovery had
larger lesion volumes (p = 0.003) and higher NIHSS scores at
baseline (p < 0.001) as compared to the stroke survivors with
complete UEMI recovery (Table 3). Also, the motor cortex
wasmore frequently involved among the survivors with worse
UEMI recovery (p = 0.03) (Table 3).
Activity Limitations and Participation Restrictions
in Stroke Patients with UEMI
The assessment of functional independence in ADLwithmRS
among the 10 individuals with residual UEMI at follow-up
showed that 7 had no/slight disability (mRS = 0–2), 2 had
moderate disability (mRS = 3), and 1 had severe disability
(mRS = 4–5).
With regard to the functional capacity of the impaired up-
per extremity, 3/10 had full capacity (ARAT = 55–57), 1/10
had notable capacity (ARAT = 43–54), 1/10 had limited ca-
pacity (ARAT = 22–42), whereas 1/10 had poor capacity
(ARAT = 11–21) and 4/10 showed no functional capacity
(ARAT = 0–10).
In total, 9/10 individuals with residual UEMI reported
problems in ADL and all 10 of them described difficulties in
social participation as assessed with the SIS. However, the
overall health status was described as Bvery good^ by 1/10
individuals with residual UEMI, as Bgood^ by 3/10, and
Bfairly good^ by 4/10, while 2/10 described it as Bpoor.^
Moreover, UEMI correlated to dependency in ADL as
evaluated with mRS (rs = 0.49, p < 0.001). Likewise, UEMI
was also correlated to the SIS domains concerning ADL (r-
s = −0.41, p < 0.001) and social participation (rs = −0.38,
p = 0.001), as well as to the patient-reported overall health
status as assessed by SF-36 (rs = −0.27, p = 0.018) (Fig. 4).
Discussion
Our study shows that UEMI was prevalent in this selected
group of ischemic stroke patients potentially suitable for
SCT, as roughly 50% had UEMI in the first days post stroke.
Moreover, nearly 25% of the subjects with UEMI at baseline
had residual impairment after 3–5 years of which half
displayed either poor or no upper extremity functional capac-
ity. However, there was considerable variability in the spon-
taneous recovery of UEMI and about 75% of the subjects with
UEMI at baseline eventually recovered completely. In addi-
tion, UEMI was strongly correlated to dependency in daily
activities and participation restrictions after stroke.
The primary patient selection objective for the present
study aimed for detecting potential candidates for SCT. To
the best of our knowledge, this is the first study to report the
frequency of UEMI in such a selected group of ischemic
stroke patients. Nearly 52% of the patients in our study
displayed UEMI in the first days after stroke. Previous
community- and population-based stroke studies have report-
ed a high prevalence of upper limb motor deficits in the acute
phase, ranging between approximately 70 and 80% [34, 35].
Fig. 3 Bubble plot illustrating
the spontaneous recovery of
upper extremity motor
impairment (n = 41 stroke
survivors without recurrent
stroke), defined as a change in
scores on the combined arm/hand
items of the National Institutes of
Health Stroke Scale between
baseline and follow-up (ΔNIHSS
arm/hand). Median ΔNIHSS
arm/hand = −1 (range −3 to 1).
The bubble size indicates the
number of subjects
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Another community-based study described a prevalence of
45% regarding upper limb motor dysfunction after 6 months
post stroke [36]. Most of these previous epidemiological stud-
ies on post-stroke UEMI were performed several years (and
sometimes decades) ago [34–36]. A more recent hospital-
based study reported that 48% of the patients in a non-
selected group with first-ever stroke had UEMI within 72 h
of onset [37]. However, the comparison between studies is
difficult because of different study designs, assessment
methods, and case mix. Nevertheless, our findings of a high
proportion of subjects with UEMI in this selected group of
ischemic stroke patients are in accordance with the previous
studies reporting a high prevalence of UEMI after stroke.
Our study also highlights the variability in spontaneous
recovery of UEMI after stroke, as many stroke patients
displayed a complete recovery whereas some only had partial
recovery and others had none (Fig. 3). This is consistent with
previous studies which have shown considerable inter-
individual variability in the course and degree of spontaneous
recovery of post-stroke UEMI [7, 38]. To assess determinants
of UEMI recovery was beyond the scope of this study due to
the limited size of the study cohort. Nevertheless, there
seemed to be a trend towards a higher degree of initial paresis
in the arm/hand, larger lesion volumes, as well as higher fre-
quency of motor cortex involvement among the stroke pa-
tients with partial or no UEMI recovery as compared to those
with complete recovery. In line with these findings, previous
studies have reported that important predictors of UEMI re-
covery include not only initial degree of severity of paresis
and lesion size but also lesion location as well as the extent of
injury on descending motor pathways, age, and comorbid
medical conditions including depression and cognitive impair-
ment [38–43]. Also, advanced neuroimaging and electrophys-
iological studies have shown that functional and structural
changes in the perilesional brain tissue as well as in more
extensive bi-hemispheric networks are important biomarkers
of recovery potential after stroke [43]. Additionally, genetic
factors such as alterations in the brain-derived neurotrophic
factor gene may influence brain plasticity and recovery after
stroke [44].
Furthermore, our results demonstrate the significance of
post-stroke UEMI as it correlates strongly to dependency in
ADL, patient-reported social participation restrictions, and
patient-reported overall health status. This is also consistent
with previous studies reporting that impaired motor functions,
and UEMI in particular, are important contributory factors in
stroke patients’ dependency in daily activities [15]. However,
even though 70% of the individuals with residual UEMI in our
study had moderate-severe impairment at follow-up and 60%
of them had either limited, poor, or no upper extremity func-
tional capacity, some of these individuals described their over-
all health status in positive terms. As previously reported, this
indicates that aspects other than impairments and disabilities
may also be important for self-perceived health and HRQoL
[45, 46], and emphasizes the importance of using both objec-
tive and patient-reported assessment measures when evaluat-
ing UEMI after stroke [47].
Taken together, our findings have several important impli-
cations for the application of SCT in stroke patients. Firstly, the
high frequency of UEMI during the first days after stroke, the
non-negligible proportion of patients with poor spontaneous
recovery and substantial residual impairment long-term after
Table 3 Characteristics of the
included ischemic stroke
survivors with no or partial UEMI
recovery versus those with
complete recovery
Variable No or partial UEMI
recovery (n = 10)
Complete UEMI
recovery (n = 31)
p value
Sex, n (%)
Female 5 (50) 10 (32) nsa
Age at stroke onset, median (range) 65 (36–74) 64 (28–75) nsb
NIHSS at baseline, median (range) 7 (2–18) 3 (1–8) <0.001b
NIHSS arm/hand at baseline, median (range) 2 (1–6) 1 (1–3) 0.004b
Lesion volume in mL, median (range) 26.5 (0.4–155.3) 1.0 (0.1–23.3) 0.003b
Lesion location, n (%)
Cortical only 0 3 (11) nsa
Subcortical only 3 (30) 16 (57) nsa
Corticosubcortical 7 (70) 7 (25) 0.02a
Motor cortex involvement, n (%) 7 (70) 8 (29) 0.03a
Corticospinal tract involvement, n (%) 8 (80) 18 (64) nsa
NIHSS National Institutes of Health Stroke Scale, including hand item 12 (composite scores 0–46); UEMI upper
extremity motor impairment, defined as the NIHSS arm/hand score of ≥1
ns not significant
a Fisher’s exact test
b The Mann-Whitney two-sample test
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stroke, as well as the strong correlation of UEMI to activity
limitations and participation restrictions suggest that SCT
targeting post-stroke UEMI may be clinically valuable with
significant meaningful benefits for patients. Secondly, the ob-
served variability in spontaneous recovery of UEMI, and the
fact that roughly three quarters of the patients with UEMI
recovered completely, emphasizes the necessity of early prog-
nostication of patients that will have residual impairment and
will be in need of a recovery-promoting treatment. From the
perspective of SCT, the ability to stratify stroke patients on the
basis of predicted potential for recovery will be central for
patient selection. Although certain predictors of UEMI recov-
ery after stroke have been previously reported, as mentioned
above, predicting such recovery in individual stroke patients is
difficult. An algorithm has recently been proposed to predict
individual stroke patients’ potential for functional recovery of
Fig. 4 Scatter plots illustrating the correlation of UEMI, as measured
with scores on the combined arm/hand items of the National Institutes
of Health Stroke Scale at follow-up (n = 76 stroke survivors without
recurrent stroke), to a dependency in daily activities according to the
modified Rankin Scale (mRS), b dependency in daily activities
according to Stroke Impact Scale (SIS) item 5, c social participation
restrictions according to SIS item 8, and d overall health status
according to the first question of Short-Form 36 Health Survey (SF-36)
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UEMI within 3 months after stroke and combines data from
clinical assessments in the acute phase (shoulder abduction and
finger extension at 72 h after symptom onset), neurophysio-
logical examination (transcranial magnetic stimulation), and
neuroimaging (DW-MRI) [48]. Another recent study reported
that scorings on two items on the ARAT, assessed at 3 days
from stroke onset, predicted the upper extremity function re-
quired for a drinking task with high accuracy during the first
year after stroke [49]. However, further studies are needed to
determine the feasibility and validity of these algorithms.
Lastly, our findings suggest that UEMI recovery is a clinically
relevant and feasible domain-specific outcome that may be
suitable as an end-point in stroke trials aiming to study the
efficacy of SCT. In addition to using established objective
assessment measures of UEMI, we recommend that such trials
also include patient-reported outcome measures to better re-
flect the patients’ perspectives with regard to their impairments
and subsequent disabilities. Hence, multiple assessment mea-
sures of UEMI could be included as a composite modality-
specific end-point that takes into account the different dimen-
sions of post-stroke UEMI, including loss of body functions
and structures (as measured with, e.g., FMA-UE), activity lim-
itations (as measured with, e.g., ARAT), and participation re-
strictions (as evaluated with, e.g., SIS or SF-36).
It should be noted, though, that there are limitations with
our study. One limitation is the hospital-based case ascertain-
ment which does not allow for a more accurate estimate of the
prevalence of post-stroke UEMI. Also, the patient selection
criteria in our study entail restrictions for a more precise esti-
mate of the overall prevalence of UEMI after stroke. However,
given the strict inclusion and exclusion criteria, our aim was to
study UEMI in this selected group of stroke patients initially
deemed to be potential SCT candidates. Moreover, many in-
cluded patients in the original study sample had mild stroke
symptoms with relatively low overall NIHSS scores. It is cur-
rently unclear if such patients will be realistic candidates for
SCT. Nonetheless, even low overall NIHSS scores may rep-
resent significant disability causing lowered HRQoL. Our
study is also limited by the relatively low number of partici-
pants and a 12% loss to follow-up (Fig. 1) which may have
caused a selective loss of patients with residual UEMI and
subsequent underestimation of the long-term post-stroke
UEMI frequency. Furthermore, there were no interim assess-
ments of the stroke patients in the period between baseline and
follow-up which might have given additional and more de-
tailed information about the natural history of spontaneous
recovery of UEMI. Besides, nearly half of the patients had
received some form of targeted rehabilitation, aiming to pro-
mote the recovery process and restore function, but we could
not evaluate the effects of rehabilitation as this was not
assessed in more detail. Finally, we defined UEMI according
to impaired performance on the NIHSS arm and/or hand items
which may have underestimated the frequency of UEMI. The
use of a more comprehensive assessment measure such as the
FMA-UE, to define UEMI at both baseline and follow-up,
might have yielded different results. It could also be argued
that the addition of the unvalidated hand item to the official
NIHSS contributes little to the measurement of the structures
underlying the NIHSS [50], but assessment of distal upper
limb motor function in addition to proximal upper limb motor
function may be of value.
In conclusion, SCT targeting post-stroke UEMI may be
clinically valuable with significant meaningful benefits for
patients since UEMI is frequent after stroke and correlates
strongly to dependency in daily activities and social participa-
tion restrictions. Our findings also demonstrate considerable
inter-individual variability in spontaneous recovery of post-
stroke UEMI, which emphasizes the necessity of validated
prognostication models that enable early stratification of pa-
tients that will have residual impairment and will be in need of
recovery-promoting treatments such as SCT.
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflicts of
interest.
Funding This study was supported by the Region Skåne, Lund
University, the Swedish Heart and Lung Foundation, the Swedish
Research Council, EU FP7 grant TargetBraIn (279017), Ragnar
Söderberg’s Foundation, the Swedish Brain Foundation, the
Freemasons Lodge of Instruction EOS Lund, and the Swedish Stroke
Association.
Research Involving Human Participants
Ethical Approval All procedures performed in this study were in ac-
cordance with the ethical standards of the institutional research committee
(the Regional Ethical Review Board in Lund, Sweden; registration num-
bers 2009/156 and 2014/298) and with the 1964 Helsinki Declaration and
its later amendments.
Informed Consent Informed consent was obtained from all individual
participants included in the study.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Lindvall O, Kokaia Z. Stem cell research in stroke: how far from the
clinic? Stroke. 2011;42:2369–75.
2. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: under-
lying mechanisms and translation to the clinic. Lancet Neurol.
2009;8:491–500.
Transl. Stroke Res.
3. Kalladka D, Muir KW. Brain repair: cell therapy in stroke. Stem
Cells Cloning. 2014;7:31–44.
4. Savitz SI, Cramer SC, Wechsler L, STEPS 3 Consortium. Stem
cells as an emerging paradigm in stroke 3: enhancing the develop-
ment of clinical trials. Stroke. 2014;45:634–9.
5. KalladkaD, Sinden J, Pollock K, Haig C,McLean J, SmithW, et al.
Human neural stem cells in patients with chronic ischaemic stroke
(PISCES): a phase 1, first-in-man study. Lancet. 2016;388:787–96.
6. Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Coburn
ML, Billigen JB, et al. Clinical outcomes of transplanted modified
bone marrow-derived mesenchymal stem cells in stroke: a phase 1/
2a study. Stroke. 2016;47:1817–24.
7. Prabhakaran S, Zarahn E, Riley C, Speizer A, Chong JY, Lazar RM,
et al. Inter-individual variability in the capacity for motor recovery
after ischemic stroke. Neurorehabil Neural Repair. 2008;22:64–71.
8. Cramer SC, Koroshetz WJ, Finklestein SP. The case for modality-
specific outcome measures in clinical trials of stroke recovery-
promoting agents. Stroke. 2007;38:1393–5.
9. Oki K, Tatarishvili J, Wood J, Koch P, Wattananit S, Mine Y, et al.
Human-induced pluripotent stem cells form functional neurons and
improve recovery after grafting in stroke-damaged brain. Stem
Cells. 2012;30:1120–33.
10. Tornero D, Wattananit S, Grønning Madsen M, Koch P, Wood J,
Tatarishvili J, et al. Human induced pluripotent stem cell-derived
cortical neurons integrate in stroke-injured cortex and improve
functional recovery. Brain. 2013;136:3561–77.
11. Hicks AU, Lappalainen RS, Narkilahti S, Suuronen R, Corbett D,
Sivenius J, et al. Transplantation of human embryonic stem cell-
derived neural precursor cells and enriched environment after cor-
tical stroke in rats: cell survival and functional recovery. Eur J
Neurosci. 2009;29:562–74.
12. Daadi MM, Maag AL, Steinberg GK. Adherent self-renewable
human embryonic stem cell-derived neural stem cell line: func-
tional engraftment in experimental stroke model. PLoS One.
2008;3(2):e1644.
13. Langhorne P, Coupar F, Pollock A. Motor recovery after stroke: a
systematic review. Lancet Neurol. 2009;8:741–54.
14. Patel AT, Duncan PW, Lai SM, Studenski S. The relation between
impairments and functional outcomes poststroke. Arch Phys Med
Rehabil. 2000;81:1357–63.
15. Veerbeek JM, Kwakkel G, van Wegen EE, Ket JC, Heymans MW.
Early prediction of outcome of activities of daily living after stroke:
a systematic review. Stroke. 2011;42:1482–8.
16. Murphy M, Resteghini C, Feys P, Lamers I. An overview of sys-
tematic reviews on upper extremity outcome measures after stroke.
BMC Neurol. 2015;15:29.
17. WHOMONICA Project Principal Investigators. The World Health
Organization MONICA Project (monitoring trends and determi-
nants in cardiovascular disease): a major international collaboration.
J Clin Epidemiol. 1988;41:105–14.
18. Brott T, Adams Jr HP, Olinger CP, Marler JR, Barsan WG, Biller J,
et al. Measurements of acute cerebral infarction: a clinical exami-
nation scale. Stroke. 1989;20:864–70.
19. Delavaran H, Sjunnesson H, Arvidsson A, Lindvall O, Norrving B,
van Westen D, et al. Proximity of brain infarcts to regions of en-
dogenous neurogenesis and involvement of striatum in ischaemic
stroke. Eur J Neurol. 2013;20:473–9.
20. WHO. International classification of functioning, disability and
health: ICF. Geneva: WHO Library Cataloguing-in-Publication
Data; 2001.
21. Wityk RJ, Pessin MS, Kaplan RF, Caplan LR. Serial assessment of
acute stroke using the NIH Stroke Scale. Stroke. 1994;25:362–5.
22. Anemaet WK. Using standardized measures to meet the challenge
of stroke assessment. Top Geriatr Rehabil. 2002;18:47–62.
23. Fugl-Meyer AR, Jääskö L, Leyman I, Olsson S, Steglind S. The
post-stroke hemiplegic patient. 1. A method for evaluation of phys-
ical performance. Scand J Rehabil Med. 1975;7:13–31.
24. Woodbury ML, Velozo CA, Richards LG, Duncan PW. Rasch
analysis staging methodology to classify upper extremity move-
ment impairment after stroke. Arch Phys Med Rehabil.
2013;94:1527–33.
25. Hoonhorst MH, Nijland RH, van den Berg JS, Emmelot CH,
Kollen BJ, Kwakkel G. How do Fugl-Meyer arm motor scores
relate to dexterity according to the action research arm test at 6
months poststroke? Arch Phys Med Rehabil. 2015;96:1845–9.
26. van Swieten JC, Koudstaal PJ, VisserMC, Schouten HJ, van Gijn J.
Interobserver agreement for the assessment of handicap in stroke
patients. Stroke. 1988;19:604–7.
27. Lyle RC. A performance test for assessment of upper limb function
in physical rehabilitation treatment and research. Int J Rehabil Res.
1981;4:483–92.
28. Yozbatiran N, Der-Yeghiaian L, Cramer SC. A standardized ap-
proach to performing the action research arm test. Neurorehabil
Neural Repair. 2008;22:78–89.
29. Duncan PW, Wallace D, Lai SM, Johnson D, Embretson S,
Laster LJ. The Stroke Impact Scale version 2.0. Evaluation of
reliability, validity, and sensitivity to change. Stroke. 1999;30:
2131–40.
30. Sullivan M, Karlsson J, Ware Jr JE. The Swedish SF-36 Health
Survey—I. Evaluation of data quality, scaling assumptions, reliabil-
ity and construct validity across general populations in Sweden. Soc
Sci Med. 1995;41:1349–58.
31. Yamada K, Kizu O, Kubota T, Ito H, Matsushima S, Oouchi H,
et al. The pyramidal tract has a predictable course through the cen-
trum semiovale: a diffusion-tensor based tractography study. J
Magn Reson Imaging. 2007;26:519–24.
32. Rorden C, Brett M. Stereotaxic display of brain lesions. Behav
Neurol. 2000;12:191–200.
33. Grönholm EO, Roll MC, Horne MA, Sundgren PC, Lindgren AG.
Predominance of caudate nucleus lesions in acute ischaemic stroke
patients with impairment in language and speech. Eur J Neurol.
2016;23:148–53.
34. NakayamaH, Jørgensen HS, Raaschou HO, Olsen TS. Recovery of
upper extremity function in stroke patients: the Copenhagen Stroke
Study. Arch Phys Med Rehabil. 1994;75:394–8.
35. Lawrence ES, Coshall C, Dundas R, Stewart J, Rudd AG,
Howard R, et al. Estimates of the prevalence of acute stroke
impairments and disability in a multiethnic population. Stroke.
2001;32:1279–84.
36. Wade DT, Hewer RL. Motor loss and swallowing difficulty after
stroke: frequency, recovery, and prognosis. Acta Neurol Scand.
1987;76:50–4.
37. Persson HC, Parziali M, Danielsson A, Sunnerhagen KS. Outcome
and upper extremity function within 72 hours after first occasion of
stroke in an unselected population at a stroke unit. A part of the
SALGOT study. BMC Neurol. 2012;12:162.
38. Cramer SC. Repairing the human brain after stroke: I. Mechanisms
of spontaneous recovery. Ann Neurol. 2008;63:272–87.
39. Stinear C. Prediction of recovery of motor function after stroke.
Lancet Neurol. 2010;9:1228–32.
40. Stinear CM, ByblowWD,Ward SH. An update on predictingmotor
recovery after stroke. Ann Phys Rehabil Med. 2014;57:489–98.
41. Lindenberg R, Renga V, Zhu LL, Betzler F, Alsop D, Schlaug G.
Structural integrity of corticospinal motor fibers predicts motor im-
pairment in chronic stroke. Neurology. 2010;74:280–7.
42. Zhu LL, Lindenberg R, Alexander MP, Schlaug G. Lesion load of
the corticospinal tract predicts motor impairment in chronic stroke.
Stroke. 2010;41:910–5.
43. Seitz RJ, Donnan GA. Recovery potential after acute stroke. Front
Neurol. 2015;6:238.
Transl. Stroke Res.
44. Lindgren A, Maguire J. Stroke recovery genetics. Stroke. 2016;47:
2427–34.
45. Schwartz CE, Andresen EM, Nosek MA, Krahn GL, RRTC
Expert Panel on Health Status Measurement. Response shift
theory: important implications for measuring quality of life
in people with disability. Arch Phys Med Rehabil. 2007;88:
529–36.
46. Jönsson AC, Delavaran H, Iwarsson S, Ståhl A, Norrving B,
Lindgren A. Functional status and patient-reported outcome 10
years after stroke: the Lund Stroke Register. Stroke. 2014;45:
1784–90.
47. Persson HC, Danielsson A, Sunnerhagen KS. A cross sectional
study of upper extremity strength ten days after a stroke;
relationship between patient-reported and objective measures.
BMC Neurol. 2015;15:178.
48. Stinear CM, Barber PA, Petoe M, Anwar S, Byblow WD. The
PREP algorithm predicts potential for upper limb recovery after
stroke. Brain. 2012;135:2527–35.
49. Persson HC, Alt Murphy M, Danielsson A, Lundgren-Nilsson Å,
Sunnerhagen KS. A cohort study investigating a simple, early as-
sessment to predict upper extremity function after stroke—a part of
the SALGOT study. BMC Neurol. 2015;15:92.
50. Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T, et al.
Underlying structure of the National Institutes of Health Stroke
Scale: results of a factor analysis. NINDS tPA Stroke Trial
Investigators. Stroke. 1999;30:2347–54.
Transl. Stroke Res.
